Alnylam Pharmaceuticals (ALNY)

$166.36 1.29 (0.78%)

17:18 EST ALNY Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 16.72B

PE Ratio -29.81

EPS -5.58

Volume (Avg. Vol.) 711,600

Day's Range 165.35 - 171.01

52-Week Range 84.97 - 175.41

Dividend & Yield N/A (N/A)

ALNY Stock Predictions, Articles, and Alnylam Pharmaceuticals News

From InvestorPlace
From the Web

Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

By James Brumley, InvestorPlace Feature Writer May 20, 2019

Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.

7 Lucrative Biotech Stocks With Up to 300% Upside

By Harriet Lefton, Writer, TipRanks Sep 6, 2018

These seven biotech stocks all have support from Wall Street's top-performing analysts and have eye-watering upside potential ahead.

8 Undervalued Biotech Stocks to Watch

By Josh Enomoto, InvestorPlace Contributor Aug 20, 2018

Volatility across all categories of biotech stocks makes this present juncture an ideal time to consider picking up undervalued names.

Alnylam Pharmaceuticals (ALNY) a Buy on Healthy Quant Score

By Portfolio Grader Nov 6, 2017

Currently, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough

By Karl Utermohlen, InvestorPlace Writer Sep 20, 2017

Alnylam Pharmaceuticals (ALNY) shares skyrocketed more than 50% on Wednesday morning on the news that the company's latest drug impressed.

4 Biotech Stocks That More Than Doubled This Year

By Zacks Investment Research Sep 5, 2017

The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than dou...

3 Pivotal Drug Trials to Watch for Explosive Potential

By Samuel Rae, InvestorPlace Contributor Jun 29, 2017

Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon.

5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now

By Zacks Investment Research Apr 12, 2017

Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

Is Now the Time to Buy Into These 5 Biotech ETFs?

By Zacks Investment Research Mar 14, 2017

After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out

Why Alnylam Pharmaceuticals, Inc. Stock Is a 2017 Winner (ALNY)

By Street Authority Jan 9, 2017

The pharmaceutical sector is well known as one of the most volatile and lucrative stock market sectors, and we've found a winner for 2017...

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 12, 2016

This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 5, 2016

The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

52 Biotechnology Stocks to Sell Now

By Portfolio Grader Nov 14, 2016

The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").